Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research

被引:196
作者
Danhof, Meindert [1 ]
de Lange, Elizabeth C. M. [1 ]
Della Pasqua, Oscar E. [1 ]
Ploeger, Bart A. [2 ]
Voskuyl, Rob A. [1 ]
机构
[1] Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Pharmacol, NL-2300 RA Leiden, Netherlands
[2] LAP&P Consultants BV, NL-2333 CM Leiden, Netherlands
关键词
D O I
10.1016/j.tips.2008.01.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The use of pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research is a promising approach that provides better understanding of drug efficacy and safety. It is applied to predict efficacy and safety in humans using in vitro bioassay and/or in vivo animal data. Current research in PK-PD modeling focuses on the development of mechanism-based models with improved extrapolation and prediction properties. A key element in mechanism-based PK-PD modeling is the explicit distinction between parameters for describing (i) drug-specific properties and (ii) biological system-specific properties. Mechanism-based PK-PD models contain specific expressions for the characterization of processes on the causal path between drug exposure and drug response. The different terms represent: target-site distribution, target binding and activation and transduction. Ultimately, mechanism-based PK-PD models will also characterize the interaction of the drug effect with disease processes and disease progression. In this review, the principles of mechanism-based PK-PD modeling are described and illustrated by recent applications.
引用
收藏
页码:186 / 191
页数:6
相关论文
共 25 条
[1]   Drug treatment effects on disease progression [J].
Chan, PLS ;
Holford, NHG .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :625-659
[2]   Mechanism-based pharmacokinetic-pharmacodynamic modeling - A new classification of biomarkers [J].
Danhof, M ;
Alvan, G ;
Dahl, SG ;
Kuhlmann, J ;
Paintaud, G .
PHARMACEUTICAL RESEARCH, 2005, 22 (09) :1432-1437
[3]  
DANHOF M, 2007, COMPREHENSIVE MED CH, V2, P885
[4]   Mechanism-based pharmacokinetic-pharmacodynamic modeling: Biophase distribution, receptor theory, and dynamical systems analysis [J].
Danhof, Meindert ;
de Jongh, Joost ;
De lange, Elizabeth C. M. ;
Della Pasqua, Oscar ;
Ploeger, Bart A. ;
Voskuyl, Rob A. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2007, 47 :357-400
[5]   A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus [J].
de Winter, Willem ;
DeJongh, Joost ;
Post, Teun ;
Ploeger, Bart ;
Urquhart, Richard ;
Moules, Ian ;
Eckland, David ;
Danhof, Meindert .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2006, 33 (03) :313-343
[6]   Markers of disease severity in chronic obstructive pulmonary disease [J].
Franciosi, LG ;
Page, CP ;
Celli, BR ;
Cazzola, M ;
Walker, MJ ;
Danhot, M ;
Rabe, KF ;
Della Pasqua, OE .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2006, 19 (03) :189-199
[7]   Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat [J].
Geldof, Marian ;
Freijer, Jan ;
van Beijsterveldt, Ludy ;
Danhof, Meindert .
PHARMACEUTICAL RESEARCH, 2008, 25 (04) :792-804
[8]   Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux [J].
Groenendaal, D. ;
Freijer, J. ;
de Mik, D. ;
Bouw, M. R. ;
Danhof, M. ;
de Lange, E. C. M. .
BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (05) :701-712
[9]   Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG [J].
Groenendaal, D. ;
Freijer, J. ;
de Mik, D. ;
Bouw, M. R. ;
Danhof, M. ;
de Lange, E. C. M. .
BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (05) :713-720
[10]   Modeling of corticosteroid effects on hepatic low-density lipoprotein receptors and plasma lipid dynamics in rats [J].
Hazra, Anasuya ;
Pyszczynski, Nancy A. ;
DuBois, Debra C. ;
Almon, Richard R. ;
Jusko, William J. .
PHARMACEUTICAL RESEARCH, 2008, 25 (04) :769-780